What is the current stock price of BioInvent International AB (publ) (BOVNF)?

As of the latest market data, BioInvent International AB (publ) (BOVNF) is trading at $3.29. The stock has seen a loss of 0.00% today.

Does BioInvent International AB (publ) (BOVNF) pay a dividend?

Based on current data, BioInvent International AB (publ) does not have a confirmed active dividend policy.

What is the market cap of BioInvent International AB (publ)?

The current market capitalization of BioInvent International AB (publ) (BOVNF) is approximately unavailable.

BOVNF

BioInvent International AB (publ)·Healthcare

3.29

0.000%(+0.00)

Close Price

3.71

12.814%(+0.42)

Pre-Market

Last Updated: — ET

52W L: $3.2952W H: $4.70

BOVNF NEWS

accessnewswire.com

May 20

BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026

LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, May 27, 2026 at 8:00 AM EDT / 2:00 PM CEST featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer. To register, click here.

accessnewswire.com

Apr 29

Resolutions at BioInvent's Annual General Meeting 2026

LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new Board members, re-elect the Board members Natalie Berner, Leonard Kruimer, Nanna Lüneborg and Bernd Seizinger, and to implement, inter alia, a long-term incentive program. The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2025 and decided that no dividend should be declared for the financial year 2025.

accessnewswire.com

Apr 29

BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio

Events will feature expert perspectives on BI-1808 in ovarian cancer and T‑cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, will host two Key Opinion Leader (KOL) events in the coming weeks, highlighting scientific and clinical progress across its BI-1808 and BI-1206 programs. Virtual KOL Event: BI‑1808 for the treatment of solid tumors BioInvent will host a virtual KOL event focused on BI-1808, the Company's novel anti‑TNFR2 antibody, and its potential role in the treatment of ovarian cancer.

accessnewswire.com

Apr 29

BioInvent International AB: Interim Report January - March 2026

LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.

accessnewswire.com

Apr 21

BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting

BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined with PD-1 blockade LUND, SE / ACCESS Newswire / April 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that additional clinical data from its ongoing Phase 2a study evaluating BI-1808 in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in advanced ovarian cancer has been selected for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago May 29 - June 2, 2026.

accessnewswire.com

Mar 31

BioInvent International AB Publishes Annual Report 2025

LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2025 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website www.bioinvent.com BioInvent's key achievements in 2025 centered on advancing the lead programs BI-1808 and BI-1206 into mid-stage clinical development, presenting encouraging data at major scientific meetings, and strengthening the financial and strategic position.

Company Profile

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Sector

Healthcare

Industry

Biotechnology

Employees

114

IPO Date

2013-09-03

Beta

-0.05

Websitewww.bioinvent.com↗